Personalizing ocrelizumab treatment in Multiple Sclerosis: What can we learn from Sars-Cov2 pandemic?

During SARS-CoV-2 pandemic, we adopted a personalized delayed protocol for ocrelizumab infusions in Relapsing Remitting Multiple Sclerosis (RRMS) patients according to the national recommendations. Out of the 83 RRMS patients whose infusion was scheduled between March and December 2020, 56 patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Tazza, F., Lapucci, C., Cellerino, M., Boffa, G., Novi, G., Poire, I., Mancuso, E., Bruschi, N., Sbragia, E., Laroni, A., Capello, E., Inglese, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2021
Materias:
Clinical Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133824/
https://www.ncbi.nlm.nih.gov/pubmed/34044238
http://dx.doi.org/10.1016/j.jns.2021.117501

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8133824/
https://www.ncbi.nlm.nih.gov/pubmed/34044238
http://dx.doi.org/10.1016/j.jns.2021.117501

Ejemplares similares